Granted Patent
B2
US 8,613,915 · App. 13/377,386 · Granted Dec 24, 2013
Attenuated strain of myxoma virus for use as an oncolytic drug
Inventors:
Stéphane Bertagnoli (Lavernose-Lacasse, FR); Magalie Gretillat (Villeurbanne, FR); Jacqueline Gelfi (Brignoles, FR); Christelle Camus-Bouclainville (Toulouse, FR)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to the use of an attenuated vaccinal strain of Myxoma virus, in particular the SG33 strain, as an oncolytic agent.
Claims (5)
1. A method of killing a cancer cell comprising contacting the cell with an attenuated SG33 strain of Myxoma virus deposited with the Collection Nationale de Cultures de Microorganismes (CNCM) under Accession No. 1-1594.
2. The method of claim 1 wherein the cancer cell is present in a human subject.
3. The method of claim 2 wherein the cancer cell is selected from the group consisting of colorectal, pancreatic and ovarian cancer cells.
4. The method of claim 1 wherein the cancer cell is present in a glial tumor.
5. The method of claim 4 wherein the glial tumor is a glioblastoma.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 19, 2012
From: BERTAGNOLI, STEPHANE; GRETILLAT, MAGALIE; GELFI, JACQUELINE; CAMUS-BOUCLAINVILLE, CHRISTELLE
To: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE; ECOLE NATIONALE VETERINAIRE TOULOUSE
Reel/Frame 027561/0790 →
Priority Claims (1)
FR 09 02835
· Jun 11, 2009
· national
Continuity (1)